Are there unique autoantigens triggering autoimmune diseases?

Immunological Reviews

Volumn 164, Issue , 1998, Pages 139-155

  Bach, J F ^a   Koutouzov, S ^a   Van Endert, P M ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CHOLINERGIC RECEPTOR; CYTOKINE; EPITOPE; GLUTAMATE DECARBOXYLASE; HISTONE; INSULIN;

ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HEREDITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUSCLE CELL; MYASTHENIA GRAVIS; NUCLEOSOME; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SKELETAL MUSCLE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TARGET CELL;

AUTOANTIGENS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, IMMUNOLOGICAL; MYASTHENIA GRAVIS;

EID: 0031726755     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01216.x     Document Type: Article

References (143)

1. Avrameas S, Ternynck T. Natural autoantibodies: the other side of the immune system. Res Immunol 1995;146:235-248.
2. Shanmugam A, et al. Healthy monozygous twins do not recognize identical T cell epitopes on the myelin basic protein autoantigen. Eur J Immunol 1994;24:2299-2303.
3. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-396.
4. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med 1993;177:627-636.
5. Alderuccio F, Toh BH, Tan SS, Gleeson PA, Van Driel IR. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J Exp Med 1993;178:419-426.
6. Pontes de Carvalho LC, Templeman J, Wick G, Roitt IM. The role of self-antigen in the development of autoimmunity in Obese strain chickens with spontaneous autoallergic thyroiditis. J Exp Med 1982;155:1255-1266.
7. Larger E, Becourt C, Bach JF, Boitard C. Pancreatic islet beta cells drive T cell-immune responses in the nonobese diabetic mouse model. J Exp Med 1995;181:1635-1642.
8. Cho BY, et al. Changes in thyrotropin receptor antibody after subtotal thyroidectomy in Graves' disease: comparison with the degree of lymphocytic infiltration in the thyroid. Autoimmunity 1990;8:143-147.
9. Irvine WJ, et al. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes 1977;26:138-147.
10. Jaeger C, et al. Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 1997;29:510-515.
11. Sutherland DE, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984;97:80-87.
12. Cardona A, Pritsch O, Dumas G, Bach JF, Dighiero G. Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. Mol Immunol 1995;32:1215-1223.
13. Jury KM, Loefller D, Eiermann TH, Ziegler B, Boehm BO, Richter W. Evidence for somatic mutation and affinity maturation of diabetes associated human autoantibodies to glutamate decarboxylase. J Autoimmun 1996;9:371-377.
14. Prentice L, et al. Monoclonal thyroglobulin autoantibodies: variable region analysis and epitope recognition. J Clin Endocrin Metab 1995;80:977-986.
15. Davis MM, Buxbaum J, eds. T-cell receptor use in human autoimmune diseases. Ann N Y Acad Sci 1995;756:1-164.
16. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995;16:176-181.
17. Sarukhan A, Bedossa P, Garchon HJ, Bach JF, Carnaud C. Molecular analysis of TCR junctional variability in individual infiltrated islets of non-obese diabetic mice: evidence for the constitution of largely autonomous T cell foci within the same pancreas. Int Immunol 1995;7:139-146.
18. Moghaddam PH, et al. Genetic structure of IDDM1: Two separate regions in the major histocompatibility complex contribute to susceptibility or protection. Diabetes 1998;47:263-269.
19. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15:516-542.
20. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599-604.
21. Kwok WW, Domeier ML, Raymond FC, Byers P, Nepom GT. Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase. J Immunol 1996;156:2171-2177.
22. Lund T, et al. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A beta-chain or normal I-E alpha-chain. Nature 1990;345:727-729.
23. Hammer J, et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 1995;181:1847-1855.
24. Wicker LS, Todd JA, Peterson LB. Genetic control of autoimmune diabetes in the NOD mouse. Annu Rev Immunol 1995;13:179-200.
25. Robinson CP, et al. A novel NOD-derived murine model of primary Sjögren's syndrome. Arthritis Rheum 1998;41:150-156.
26. Luhder F, Katz J, Benoist C, Mathis D. Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. J Exp Med 1998;187:379-387.
27. Schmidt D, Verdaguer J, Averill N, Santamaria P. A mechanism for the major histocompatibility complex-linked resistance to autoimmunity. J Exp Med 1997;186:1059-1075.
28. Carrasco-Marin E, Shimizu J, Kanagawa O, Unanue ER. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders. J Immunol 1996;156:450-458.
29. Buckner J, Kwok WW, Nepom B, Nepom GT. Modulation of HLA-DQ binding properties by differences in class II dimer stability and pH-dependent peptide interactions. J Immunol 1996;157:4940-4945.
30. Thomson G, et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet 1988;43:799-816.
31. Nepom GT, Erlich H. MHC class-II molecules and autoimmunity. Annu Rev Immunol 1991;9:493-525.
32. Wicker LS, et al. Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401. J Clin Invest 1996;98:2597-2603.
33. Patel SD, et al. Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha 1*0101,beta 1*0401) transgenic mice. Proc Natl Acad Sci USA 1997;94:8082-8087.
34. Verge CF, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin. GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-933.
35. Atkinson MA, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992;339:458-459.
36. Harrison LC, et al. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 1993;341:1365-1369.
37. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-75.
38. Kaufman DL, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72.
39. Gelber C, et al. Isolation of nonobese diabetic mouse T-cells that recognize novel autoantigens involved in the early events of diabetes. Diabetes 1994;43:33-39.
40. Wegmann DR, Norbury-Glaser M, Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994;24:1853-1857.
41. Zekzer D, et al. GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 1998;101:68-73.
42. Muir A, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995;95:628-634.
43. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991;88:10252-10256.
44. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994;343:704-706.
45. French MB, et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997;46:34-39.
46. Birk OS, et al. A role of hsp60 in autoimmune diabetes: analysis in a transgenic model. Proc Natl Acad Sci USA 1996;93:1032-1037.
47. Oshima M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T cell recognition of human acetylcholine receptor: the sites of T cell recognition in myasthenia gravis on the extracellular part of the alpha subunit. Eur J Immunol 1990;20:2563-2569.
48. Berrih-Aknin S, Cohen-Kaminsky S, Neumann D, Bach JF, Fuchs S. Proliferative responses to acetylcholine receptor peptides in myasthenia gravis. Ann N Y Acad Sci 1988;540:504-505.
49. Lubke E, et al. Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes. J Neuroimmunol 1998;81:98-108.
50. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989;44:93-151.
51. Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 1993;69:494-507.
52. Hardin JA. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1986;29:457-460.
53. Izui S, Lambert PH, Miescher PA. Failure to detect circulating DNA-anti-DNA complexes by four radioimmunological methods in patients with systemic lupus erythematosus. Clin Exp Immunol 1977;30:384-392.
54. Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990;86:69-74.
55. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-1330.
56. Aringer M, et al. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1423-1430.
57. Strasser A, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991;88:8661-8665.
58. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-3692.
59. Van Houten N, Budd RC. Accelerated programmed cell death of MRL-lpr/lpr T lymphocytes. J Immunol 1992;149:2513-2517.
60. Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992;90:1067-1076.
61. Amoura Z, et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus - Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum 1997;40:2217-2225.
62. Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993;91:1687-1696.
63. Amoura Z, et al. Nucleosome-restricted antibodies are detected before anti-dsDNA and/or antihistone antibodies in serum of MRL-Mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 1994;37:1684-1688.
64. Losman MJ, Fasy TM, Novick KE, Monestier M. Monoclonal autoantibodies to subnucleosomes from a MRL/Mp(-)+/+ mouse. Oligoclonality of the antibody response and recognition of a determinant composed of histones H2A, H2B, and DNA. J Immunol 1992;148:1561-1569.
65. Brard F, Jovelin F, Petit S, Tron F, Gilbert D. Structural properties and mutation patterns of anti-nucleosome monoclonal antibodies are similar to those of anti-DNA antibodies. Eur J Immunol 1996;26:1587-1594.
66. Jovelin F, et al. Early anti-nucleosome autoantibodies from a single MRL+/+ mouse: fine specificity, V-gene structure and pathogenicity (Submitted).
67. Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994;94:184-192.
68. Chabre H, Amoura Z, Piette JC, Godeau P, Bach JF, Koutouzov S. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995;38:1485-1491.
69. Shlomchik M, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med 1990;171:265-292.
70. Eilat D, Fischel R. Recurrent utilization of genetic elements in V regions of antinucleic acid antibodies from autoimmune mice. J Immunol 1991;147:361-368.
71. Monestier M, Fasy TM, Losman MJ, Novick KE, Muller S. Structure and binding properties of monoclonal antibodies to core histones from autoimmune mice. Mol Immunol 1993;30:1069-1075.
72. Koutouzov S, Jovelin F, Brard F, Raux G, Tron F, Gilbert D. Comparison of structural characteristics of anti-subnucleosome and anti-DNA monoclonal antibodies derived from lupus mice. Ann N Y Acad Sci 1997;815:327-330.
73. Mao C, Osman GE, Adams S, Datta SK. T cell receptor alpha-chain repertoire of pathogenic autoantibody-inducing T cells in lupus mice. J Immunol 1994;152:1462-1470.
74. Daniel D, Gill RG, Schloot N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995;25:1056-1062.
75. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996;93:956-960.
76. Von Herrath MG, Dyrberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996;98:1324-1331.
77. Tompkins SM, Moore JC, Jensen PE. An insulin peptide that binds an alternative site in class II major histocompatibility complex. J Exp Med 1996;183:857-866.
78. Simone E, et al. T cell receptor restriction of diabetogenic autoimmune NOD T cells. Proc Natl Acad Sci USA 1997;94:2518-2521.
79. Palmer JP, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-1339.
80. Schloot NC, et al. Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects. Diabetologia 1997;40:564-572.
81. Naquet P, et al. T cell autoreactivity to insulin in diabetic and related non-diabetic individuals. J Immunol 1988;140:2569-2578.
82. Tian J, Lehmann PV, Kaufman DL. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens. J Exp Med 1997;186:2039-2043.
83. Tian J, Lehmann PV, Kaufman DL. T cell cross-reactivity between coxsackievirus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med 1994;180:1979-1984.
84. Hanson MS, et al. Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. J Immunol 1996;157:1279-1287.
85. Quinn A, Sercarz EE. T cells with multiple fine specificities are used by non-obese diabetic (NOD) mice in the response to GAD(524-543). J Autoimmun 1996;9:365-370.
86. Chao CC, McDevitt HO. Identification of immunogenic epitopes of GAD 65 presented by Ag7 in non-obese diabetic mice. Immunogenetics 1997;46:29-34.
87. Tian J, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183:1561-1567.
88. Ma SW, et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 1997;3:793-796.
89. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliot JF, Leiter EH. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens. Diabetes 1997;46:1975-1982.
90. Lenschow DJ, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-293.
91. Schloot NC, Daniel D, Norbury-Glaser M, Wegmann DR. Peripheral T cell clones from NOD mice specific for GAD65 peptides: lack of islet responsiveness or diabetogenicity. J Autoimmun 1996;9:357-363.
92. Lohmann T, Leslie RD, Hawa M, Geysen M, Rodda S, Londei M. Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus. Lancet 1994;343:1607-1608.
93. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, MacLaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994;94:2125-2129.
94. Lohmann T, Leslie RDG, Londei M. T cell clones to epitopes of glutamic acid decarboxylase 65 raised from normal subjects and patients with insulin-dependent diabetes. J Autoimmun 1996;9:385-389.
95. Bach JM, et al. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J Autoimmun 1997;10:375-386.
96. Endl J, et al. Identification of naturally processed T cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 1997;99:2405-2415.
97. Harcourt GC, Sommer N, Rothbard J, Willcox HN, Newsom-Davis J. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J Clin Invest 1988;82:1295-1300.
98. Melms A, et al. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989;83:785-790.
99. Salvetti M, Jung S, Chang SF, Will H, Schalke BC, Wekerle H. Acetylcholine receptor-specific T-lymphocyte clones in the normal human immune repertoire: target epitopes. HLA restriction, and membrane phenotypes. Ann Neurol 1991;29:508-516.
100. Moiola L, Protti MP, Manfredi AA, Yuen MH, Howard JF Jr, Conti-Tronconi BM. T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann N Y Acad Sci 1993;681:198-218.
101. Protti MP, Manfredi AA, Wu XD, Moiola L, Howard JF Jr, Conti-Tronconi BM. Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor. J Immunol 1991;146:2253-2261.
102. Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol Today 1996;17:307-311.
103. Rajagopalan S, Zordan T, Tsokos GC, Datta SK. Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA 1990;87:7020-7024.
104. Adams S, Zordan T, Sainis K, Datta S. T cell receptor V beta genes expressed by IgG anti-DNA autoantibody-inducing T cells in lupus nephritis: forbidden receptors and double-negative T cells. Eur J Immunol 1990;20:1435-1443.
105. Sainis K, Datta SK. CD4+ T cell lines with selective patterns of autoreactivity as well as CD4- CD8- T helper cell lines augment the production of idiotypes shared by pathogenic anti-DNA autoantibodies in the NZB x SWR model of lupus nephritis. J Immunol 1988;140:2215-2224.
106. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-1381.
107. Desai-Mehta A, Mao C, Rajagopalan S, Robinson T, Datta SK. Structure and specificity of T cell receptors expressed by potentially pathogenic anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 1995;95:531-541.
108. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996;183:2459-2469.
109. Hoffman RW, et al. Human T cell clones reactive against U-small nuclear ribonucleoprotein autoantigens from connective tissue disease patients and healthy individuals. J Immunol 1993;151:6460-6469.
110. Crow MK, et al. Autoantigen-specific T cell proliferation induced by the ribosomal P2 protein in patients with systemic lupus erythematosus. J Clin Invest 1994;94:345-352.
111. Tzartos SJ, et al. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol Neurobiol 1991;5:1-29.
112. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992;358:155-157.
113. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995;182:75-85.
114. Miller SD, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997;3:1133-1136.
115. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor alpha 138-199: determinant spreading initiates autoimmunity to self-antigen in rabbits. Immunol Lett 1994;39:269-275.
116. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-461.
117. Koutouzov S, Cabrespines A, Amoura Z, Chabre H, Lotton C, Bach JF. Binding of nucleosomes to a cell surface receptor: redistribution and endocytosis in the presence of lupus antibodies. Eur J Immunol 1996;26:472-486.
118. Bockenstedt LK, Gee RJ, Mamula MJ. Self-peptides in the initiation of lupus autoimmunity. J Immunol 1995;154:3516-3524.
119. Miller SD, et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. Immunol Rev 1995;144:225-244.
120. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993;14:203-208.
121. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983;2:1115-1119.
122. Sarvetnick N, et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990;346:844-847.
123. Allison J, Campbell IL, Morahan G, Mandel TE, Harrison LC, Miller JF. Diabetes in transgenic mice resulting from overexpression of class I histocompatibility molecules in pancreatic beta cells. Nature 1988;333:529-533.
124. Bohme J, et al. Trinsgenic mice with I-A on islet cells are normoglycemic but immunologically intolerant. Science 1989;244:1179-1183.
125. Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Rev 1995;11:83-107.
126. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987;2:1423-1427.
127. Campbell IL, Oxbrow L, Koulmanda M, Harrison LC. IFN-gamma induces islet cell MHC antigens and enhances autoimmune, streptozotocin-induced diabetes in the mouse. J Immunol 1988;140:1111-1116.
128. Shewey LM, Beaty JS, Andersen LC, Nepom GT. Differential expression of related HLA class II DQ beta genes caused by nuleotide variation in transcriptional regulatory elements. J Immunol 1992;148:1265-1273.
129. Streit WJ, Graeber MB, Kreutzberg GW. Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp Neurol 1989;105:115-126.
130. Streit WJ, Graeber MB, Kreutzberg GW. Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system. J Neuroimmunol 1989;21:117-123.
131. Neumann H, Boucraut J, Hahnel C, Misgeld T, Wekerle H. Neuronal control of MHC class II inducibility in rat astrocytes and microglia. Eur J Neurosci 1996;8:2582-2590.
132. Stephens LA, Kay TW. Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. Int Immunol 1995;7:1885-1895.
133. Wong S, et al. Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse. Diabetes 1995;44:326-329.
134. Miller SD, et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995;3:739-745.
135. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 1995;181:1945-1948.
136. Cooke MS, Mistry N, Wood C, Herbert KE, Lunec J. Immunogenicity of DNA damaged by reactive oxygen species-implications for anti-DNA antibodies in lupus. Free Radic Biol Med 1997;22:151-159.
137. Casciola-Rosen LA, Miller DK, Anhalt GJ, Rosen A. Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. J Biol Chem 1994;269:30757-30760.
138. Cabrespines A, Laderach D, Lebossé C, Bach JF, Koutouzov S. Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody, generated during hybridoma B-cell apoptosis. J Autoimmun 1998;11:19-27.
139. Rekvig OP, et al. Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J Clin Invest 1997;99:2045-2054.
140. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens are generated during apoptosis. J Exp Med 1995;181:1557-1561.
141. Emlen W, Holers VM, Arend WP, Kotzin B. Regulation of nuclear antigen expression on the cell surface of human monocytes. J Immunol 1992;148:3042-3048.
142. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
143. Bockova J, Elias D, Cohen IR. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces th2-type antibodies. J Autoimmun 1997;10:323-329.